In the pharmaceutical and biotech
sectors, companies depend on alliances and partnerships throughout
the course of the drug development and medical product development
lifecycle. These alliances are critical to their success.
Pharma and Biotech companies are immersed in the development,
testing and delivery of new medical cures and products that treat
disease, extend life and improve the quality of life.
Often, a critical component of their success lies in their ability
to establish and effectively manage alliances and partnerships that
may be used in one to several of the phases of a drug or product’s
development and delivery lifecycle.
With this lifecycle that can take over a decade to complete and can
cost in the billions of dollars, it is critical to continuously
improve the effectiveness of these partnerships in terms of both
money and time in order to improve the drug or product’s revenue
potential and profitability.
significant market drivers that are causing an increased interest in
creating additional alliance and partner effectiveness between
Pharma and Biotech companies that include:
Pharma and Biotech development costs
generate cash flow
Upcoming patent expirations
companies’ evolution to having a full commercialization
downstream technology expertise
regulatory and marketing strength
Increase company value
population (more drugs, therapies and technologies will be
Decreases in size workforce
The result of these drivers is that as the reliance on alliances and
partnerships continue to increase, pharma and biotech companies must
constantly improve their effectiveness in order to compete.
Not unlike alliances and
partnerships in other market sectors, Pharma and Biotech alliances
have similar alliance issues that need to be addressed.
AllianceAnalytics has found that this common thread of issues can be
found in business to business alliance and business partner
Specifically, in the Pharma and
Biotech space, there are several consistent alliance and partnership
issues, which include:
Different Corporate Cultures
Personnel Turnover – Decreasing
Dependency on Alliance Team
Members to overcome obstacles
20-33% of Alliances are
restructured or cancelled
No ability to capture knowledge
or develop predictive analytics
There are multiple alliance types
within the Pharma and Biotech market just as there are in the other
Partner Value Optimizer markets. The alliance and business
partnership types are shown in the diagram below.
offers a truly
innovative and revolutionary solution for Pharma and Biotech
companies seeking to continuously optimize development time, results
and product revenues while decreasing the costs of their alliances
Optimizer™ (PVO™) captures,
analyzes and presents all of the
unstructured, causal and soft skills data needed to determine the effectiveness
and value of partnering processes, policies, personnel and programs
and their individual and combined impact on results for all phases
of the drug development lifecycle.
PVO™ is an
exclusive and Patent-pending software solution which enables
companies to create the analytics and business intelligence
needed to make more informed partnering decisions in order to create
measurable value and gain a substantial competitive advantage from
their alliances and partnerships.